AKT1 and breast cancer: Initially, Akl reported that sesamin (10-120 μM) with γ-tocotrienol synergistically inhibits growth-mediated EGF-dependent by decreasing phosphorylation of ErbB3 and ErbB4 receptor and mitogenic signaling, i.e., suppressed intracellular and phosphorylated oncogene c-Raf, MAPK/ERK kinase, extracellular signal-regulated kinase 1/2, phosphoinositide-dependent kinase-1, phosphoinositide-3-kinase, protein kinase B, p-NF-κB, JAK1, JAK 2, and STAT1 at a dose-dependent manner in mammary tumor cells [91].